A prospective, single-arm, open-label, non-randomized, phase IIa trial of a nonavalent prophylactic HPV vaccine to assess immunogenicity of a prime and deferred-booster dosing schedule among 9–11 year-old girls and boys – clinical protocol
Abstract Background Human papillomavirus (HPV) vaccines are indicated for the prevention of cancers and genital warts caused by vaccine-covered HPV types. Although the standard regimen requires a two or three-dose vaccine series, there is emerging data suggesting that a single dose of the bivalent o...
Main Authors: | Yi Zeng, Anna-Barbara Moscicki, Vikrant V. Sahasrabuddhe, Francisco Garcia, Heide Woo, Chiu-Hsieh Hsu, Eva Szabo, Eileen Dimond, Susan Vanzzini, Angelica Mondragon, Valerie Butler, Hillary DeRose, H.-H. Sherry Chow |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-04-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-019-5444-4 |
Similar Items
-
Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain
by: Jesús De La Fuente, et al.
Published: (2019-08-01) -
Prophylactic Human Papillomavirus Vaccination: From the Origin to the Current State
by: Ayazhan Akhatova, et al.
Published: (2022-11-01) -
Potential impact of a nonavalent HPV vaccine on HPV related low-and high-grade cervical intraepithelial lesions: A referral hospital-based study in Sicily
by: Giuseppina Capra, et al.
Published: (2017-08-01) -
Defining Elimination of Genital Warts—A Modified Delphi Study
by: Laila Khawar, et al.
Published: (2020-06-01) -
Statistical Study: Vaccination Against HPV Among Dental Students in Romania
by: Elena Cristina ANDREI, et al.
Published: (2022-12-01)